Westfield Capital Management Co. LP Invests $11.38 Million in Cantel Medical Corp. (CMD)

Westfield Capital Management Co. LP acquired a new position in shares of Cantel Medical Corp. (NYSE:CMD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 120,830 shares of the company’s stock, valued at approximately $11,379,000. Westfield Capital Management Co. LP owned approximately 0.29% of Cantel Medical at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of CMD. First Trust Advisors LP increased its stake in Cantel Medical by 6.8% in the 3rd quarter. First Trust Advisors LP now owns 11,677 shares of the company’s stock worth $1,100,000 after buying an additional 739 shares during the period. Rhumbline Advisers increased its stake in Cantel Medical by 1.2% in the 3rd quarter. Rhumbline Advisers now owns 76,496 shares of the company’s stock worth $7,204,000 after buying an additional 870 shares during the period. Aperio Group LLC increased its position in Cantel Medical by 8.4% during the 3rd quarter. Aperio Group LLC now owns 13,894 shares of the company’s stock valued at $1,308,000 after purchasing an additional 1,075 shares during the period. Globeflex Capital L P purchased a new position in Cantel Medical during the 2nd quarter valued at about $114,000. Finally, American International Group Inc. grew its position in shares of Cantel Medical by 5.4% in the 3rd quarter. American International Group Inc. now owns 28,684 shares of the company’s stock worth $2,701,000 after buying an additional 1,464 shares during the last quarter. 84.98% of the stock is currently owned by institutional investors and hedge funds.

Cantel Medical Corp. (NYSE:CMD) traded down $2.89 during trading on Wednesday, reaching $100.49. The company had a trading volume of 208,500 shares, compared to its average volume of 146,027. The stock has a market cap of $4,321.89, a PE ratio of 49.70 and a beta of 1.24. Cantel Medical Corp. has a 1 year low of $69.21 and a 1 year high of $108.00. The company has a current ratio of 2.41, a quick ratio of 1.49 and a debt-to-equity ratio of 0.24.

Cantel Medical (NYSE:CMD) last released its quarterly earnings results on Thursday, September 28th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.52 by $0.02. The firm had revenue of $205.50 million for the quarter, compared to analyst estimates of $200.32 million. Cantel Medical had a return on equity of 17.60% and a net margin of 9.27%. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. equities research analysts predict that Cantel Medical Corp. will post 2.34 EPS for the current fiscal year.

The firm also recently disclosed a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, January 17th will be issued a dividend of $0.085 per share. The ex-dividend date is Tuesday, January 16th. This is an increase from Cantel Medical’s previous Semi-Annual dividend of $0.07. This represents a yield of 0.17%. Cantel Medical’s payout ratio is currently 8.19%.

In other news, Chairman Charles M. Diker sold 20,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $99.15, for a total value of $2,032,575.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark N. Diker sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $98.90, for a total value of $692,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,368 shares of company stock worth $3,576,028 over the last 90 days. 12.30% of the stock is owned by company insiders.

Several equities research analysts recently commented on CMD shares. Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical in a report on Friday, September 1st. Zacks Investment Research raised Cantel Medical from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $91.67.

COPYRIGHT VIOLATION WARNING: “Westfield Capital Management Co. LP Invests $11.38 Million in Cantel Medical Corp. (CMD)” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/12/06/westfield-capital-management-co-lp-invests-11-38-million-in-cantel-medical-corp-cmd.html.

Cantel Medical Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Want to see what other hedge funds are holding CMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cantel Medical Corp. (NYSE:CMD).

Institutional Ownership by Quarter for Cantel Medical (NYSE:CMD)

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply